640P Quality of life and survival in elderly metastatic castration-resistant prostate cancer (mCRPC) patients (Pts) treated with docetaxel
Irene Paredero(Consorcio Hospitalario Provincial de Castellón), A. Sánchez-Hernández(Consorcio Hospitalario Provincial de Castellón), R. Lozano Mejorada(Spanish National Cancer Research Centre), David Lorente(Hospital Universitari i Politècnic La Fe), E. Castro Marcos(Hospital Clínico Universitario Virgen de la Victoria), David Olmos(Spanish National Cancer Research Centre), María José Domper-Arnal(Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas), Regina Gironés Sarrió(Hospital Universitari i Politècnic La Fe), Casilda Llácer Pérez(Hospital Clínico Universitario Virgen de la Victoria)
Cited by 1
Related Papers
Esophageal cancer: Risk factors, screening and endoscopic treatment in Western and Eastern countries
|World Journal of Gastroenterology|2015|1k
Germline <i>BRCA</i> Mutations Are Associated With Higher Risk of Nodal Involvement, Distant Metastasis, and Poor Survival Outcomes in Prostate Cancer
|Journal of Clinical Oncology|2013|833
Effect of BRCA Mutations on Metastatic Relapse and Cause-specific Survival After Radical Treatment for Localised Prostate Cancer
|European Urology|2014|374
Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer
|Journal of Clinical Oncology|2023|332